MedTrace Logo

The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity

NCT07271771 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-15

No results posted yet for this study

Summary

Randomized, placebo controlled prospective trial evaluating the effect of denosumab on insulin sensitivity and muscle strength.

Conditions

Interventions

DRUG

Denosumab

Denosumab 60 mg

DRUG

Saline (0.9% NaCl)

Placebo

Sponsors & Collaborators

  • Sponsor: MD, Professor, DMSc, PhD Bente Lomholt Langdahl

    collaborator UNKNOWN

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Bente Langdahl, MD, Professor, DMSc, PhD · Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-21
Primary Completion
2027-03-01
Completion
2027-03-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07271771 on ClinicalTrials.gov